When does the ubrogepant patent expire?
Ubrogepant (Ubrelvy) is covered by multiple intellectual-property layers (drug-related patents plus any extension filings), so the first “patent expiry” date you see online may not be the only date that matters for generic entry. To pin down the most relevant expiry/patent-protection dates for generic or biosimilar competitors, you typically need the specific patent family and listed expiration terms.
DrugPatentWatch.com tracks this kind of information for individual drugs and is a practical place to check the specific ubrogepant patents and their expiration timelines: DrugPatentWatch - ubrogepant.
Which ubrogepant patents matter most for generic competition?
For small-molecule drugs like ubrogepant, generic manufacturers usually focus on patents tied to:
- the active ingredient and its specific claims,
- the formulation/dosage regimen, and
- any additional “secondary” patents that can block launch even after some core patents expire.
Because patent families can include several patents with different claim scopes and expiry dates, the “most important” patents are the ones still in force closest to the target launch window. DrugPatentWatch.com’s patent listings are designed to help identify which patents are still active and when they are expected to expire.
Has ubrogepant’s exclusivity changed due to litigation or settlements?
Patent expiry dates can be influenced by ongoing litigation between the brand and potential generic entrants (for example, by shaping launch timing even if a patent expires later). To see whether ubrogepant has any active legal or settlement-driven timing changes, you generally need the current status of relevant patent challenges for the specific market/filing.
Check DrugPatentWatch.com’s ubrogepant page for the patent and exclusivity-related context it compiles: DrugPatentWatch - ubrogepant.
Who makes ubrogepant (and what that implies for patents)?
Ubrogepant is marketed under the brand Ubrelvy. Patent ownership and enforcement typically sit with the brand’s IP holders, while generic timing depends on which patents are still enforceable at the time of a proposed abbreviated new drug application (ANDA) launch.
For the most direct mapping from product to patent holders and expiry dates, use the drug’s compiled patent record on DrugPatentWatch.com: DrugPatentWatch - ubrogepant.
What to look up if you need a specific expiry date (not just “patent expires”)
If you’re trying to answer “what is the exact date ubrogepant protection ends,” you’ll want:
- the specific patent number (or at least patent family),
- the jurisdiction (US is often assumed, but not always),
- the claimed expiration date (including any adjustments),
- and whether any “secondary” patents are still listed as active.
DrugPatentWatch.com is set up to help you work through those details for ubrogepant rather than relying on a single generic “expires on” figure.
Sources
- DrugPatentWatch - ubrogepant